Latin America NGS Market: Focus on Offering, Technology, Application, and End User - Analysis and Forecast, 2024-2034
라틴아메리카의 NGS 시장 규모는 2024년에 2억 6,804만 달러에 달했습니다.
이 시장은 2034년에는 5억 9,720만 달러에 달할 것으로 예측되며, 예측 기간(2024-2034년) CAGR은 8.34%가 될 것으로 예상됩니다. NGS 수요는 종양학, 전염병 연구 및 출생 전 진단에서 용도 증가로 견인되고 있습니다.
| 주요 시장 통계 |
| 예측 기간 |
2024-2034년 |
| 2024년 평가 |
2억 6,804만 달러 |
| 2034년 예측 |
5억 9,720만 달러 |
| CAGR |
8.34% |
차세대 시퀀싱(NGS)은 여러 유전자의 동시 해석을 가능하게 하고, 종양의 정확한 프로파일링, 실용적인 변이의 특정, 표적 치료에 의한 치료 계획의 커스터마이즈를 용이하게 함으로써, 암 진단에 변혁을 가져왔습니다. NGS는 비침습적이며 혈류 중 순환 종양 DNA(ctDNA)를 분석하여 암의 진행을 추적하는데 도움이 되는 액체생검에 널리 사용되고 있습니다. 또한, 종양학의 중개 연구는 종양의 유전학을 조사하기 위해 NGS에 크게 의존하고 있으며, 암의 진행이나 치료에 대한 내성을 일으키는 유전자 변화의 동정을 가능하게 하고 있습니다. 이에 따라 신약과 표적 치료의 개발이 추진되고 있습니다.
종양학 이외에도 NGS는 비침습적 산전 검사(NIPT)에 응용되어 태아의 DNA를 분석하여 다운증후군과 같은 염색체 이상을 검출하고 있습니다. 집단의 대규모 시퀀싱을 포함한 집단 유전체학는 유전적 다양성, 유전자와 환경의 상호작용 및 질병 감수성에 대한 연구를 가능하게 합니다. 이러한 진보는 집단 특유의 유전자 프로파일에 맞춘 치료를 실시하는 맞춤형 의료에의 길을 여는 것입니다.
NGS는 또한 병원체의 검출에 중요한 역할을 합니다. 유전체 전체를 배열함으로써 감염, 특히 약물 내성 병원체의 유전체 모니터링에 도움이 됩니다. NGS는 바이러스, 박테리아 및 곰팡이의 유전자 구조에 대한 이해를 촉진하고 백신 개발 및 항바이러스 요법에 기여합니다. 이 능력은 COVID-19의 대유행을 포함하여 질병의 발생을 관리하는 데 매우 중요합니다.
라틴아메리카에서 NGS 기술의 채용은 암, 만성 질환, 희소 유전자 질환의 유병률의 상승에 의해 촉진되고 있습니다. 브라질과 멕시코 같은 국가들은 유전체 검사와 종양학에 투자하고 있으며 암 치료에 NGS 기반 진단을 통합하고 있습니다. 유전체 데이터가 보다 입수하기 쉽고, 저렴해지고, 맞춤형 의료의 성장이 촉진됨에 따라, 이러한 동향은 앞으로도 계속될 것으로 예상됩니다.
이 보고서는 라틴아메리카의 NGS 시장에 대해 조사했으며, 시장 개요와 함께 제공 제품별, 기술별, 용도별, 최종 사용자별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
목차
주요 요약
조사 범위
제1장 시장 개요
- 제품 정의
- 포함 기준과 제외 기준
- 라틴아메리카의 NGS 시장 규모, 100만 달러, 2023-2034년
- NGS의 규제 상황
- 시장 역학
- NGS 기반의 검사량 분석(적응별), 2023-2033년
- NGS 기반의 검사량 분석(국가별), 2023-2033년
- 라틴아메리카의 NGS 시장 테스트 시나리오
제2장 제공 제품별
제3장 기술별
- 성장 점유율 매트릭스
- 이온 토렌트 반도체 시퀀싱
- 가역 터미네이터 배열
- 단일 분자 실시간 시퀀싱
- 나노포어 시퀀싱 기술
- 기타
제4장 용도별
제5장 최종 사용자별
- 성장 점유율 매트릭스
- 병원 및 진료소
- 학술연구기관
- 제약 및 바이오테크놀러지 기업
- 정부 연구소
- 기타
제6장 국가별
- 개요
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 칠레
- 코스타리카
- 푸에르토리코
- 기타
제7장 경쟁 벤치마킹 및 기업 프로파일
- 라틴아메리카 NGS 시장 점유율(기업별, 2023년)
- 경쟁 벤치마킹
- 국가별 NGS 기기 설치 베이스, 2023년
- 기업 프로파일
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN NV
- PacBio
- Agilent Technologies, Inc.
- Oxford Nanopore Technologies plc
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- Revvity, Inc.
- MGI Tech Co., Ltd.
JHS
Market Overview
The Latin America NGS market was valued at $268.04 million in 2024 and is anticipated to reach $597.20 million by 2034, witnessing a CAGR of 8.34% during the forecast period 2024-2034. The demand for NGS is driven by increasing applications in oncology, infectious disease research, and prenatal diagnostics.
Market Introduction
| KEY MARKET STATISTICS |
|---|
| Forecast Period | 2024 - 2034 |
| 2024 Evaluation | $268.04 Million |
| 2034 Forecast | $597.20 Million |
| CAGR | 8.34% |
Next-generation sequencing (NGS) has transformed cancer diagnostics by enabling simultaneous analysis of multiple genes, facilitating precise tumor profiling, identifying actionable mutations, and customizing treatment plans through targeted therapies. NGS is extensively used in liquid biopsies, which are non-invasive and aid in tracking cancer progression by analyzing circulating tumor DNA (ctDNA) in the bloodstream. Moreover, translational research in oncology heavily relies on NGS to study tumor genetics, enabling the identification of genetic alterations driving cancer progression and resistance to therapies. This has propelled the development of new drugs and targeted treatments.
Beyond oncology, NGS is applied in non-invasive prenatal testing (NIPT) to detect chromosomal abnormalities, such as Down syndrome, by analyzing fetal DNA. Population genomics, involving large-scale sequencing of populations, has enabled studies on genetic diversity, gene-environment interactions, and disease susceptibility. These advancements pave the way for personalized medicine, tailoring treatments to population-specific genetic profiles.
NGS also plays a crucial role in pathogen detection. It sequences entire genomes, aiding in genomic surveillance of infectious diseases, particularly drug-resistant pathogens. NGS facilitates understanding of the genetic makeup of viruses, bacteria, and fungi, contributing to vaccine development and antiviral therapies. This capability has been critical in managing disease outbreaks, including during the COVID-19 pandemic.
The adoption of NGS technologies in Latin America has been fueled by the rising prevalence of cancer, chronic diseases, and rare genetic disorders. Countries like Brazil and Mexico are investing in genomic testing and oncology, integrating NGS-based diagnostics for cancer treatment. These trends are expected to continue as genomic data becomes more accessible and affordable, fostering the growth of personalized medicine.
Impact of COVID-19
The pandemic underscored the importance of genomic surveillance, accelerating investments in NGS infrastructure. Latin American countries utilized NGS for monitoring viral mutations and understanding the epidemiology of COVID-19. This has set the stage for enhanced genomic capabilities to manage future infectious disease threats.
Supply Chain Disruptions:
- Manufacturing and transportation challenges temporarily affected the availability of NGS instruments and consumables.
Shift to Remote Workflows:
- Increased adoption of cloud-based genomic platforms allowed continuity of research during lockdowns.
Market Segmentation:
Segmentation 1: by Offering
- Services
- The largest segment, contributing 38.50% to the market in 2023, projected to grow to 40.55% by 2034.
- Kits and Consumables
- Accounted for 34.41% of the market in 2023, expected to retain significant share due to consistent demand for consumables in NGS workflows.
- Software
- Held 8.68% in 2023, crucial for managing and analyzing large genomic datasets.
- Instruments
- Represented 18.42% of the market in 2023, with growth driven by technological advancements.
Segmentation 2: by Technology
- Reversible Terminator Sequencing
- Dominates the market with a 77.80% share in 2023, projected to grow to 83.09% by 2034 due to its efficiency and cost-effectiveness.
- Ion Torrent Semiconductor Sequencing
- Accounted for 8.65% in 2023, used for small-scale sequencing projects.
- Single Molecule Real-Time Sequencing
- Nanopore Sequencing Technology
- Other Technology
Segmentation 3: by Application
- Clinical
- Largest segment, with 52.43% in 2023, expected to grow to 56.50% by 2034. Key applications include cancer diagnostics, prenatal testing, and infectious disease management.
- Translational Research
- Accounted for 47.57% in 2023, pivotal for drug discovery and understanding disease mechanisms.
Segmentation 4: by End-User
- Academic and Research Institutes
- Largest share in 2023 (39.06%), projected to grow to 39.51% by 2034. Growth driven by increased research activities.
- Hospitals and Clinics
- Accounted for 26.90% in 2023, with adoption driven by expanding clinical applications.
- Pharmaceutical and Biotechnology Companies
- Represented 19.00% in 2023, leveraging NGS for drug development and biomarker discovery.
- Government Laboratories
- Other End User
Segmentation 5: by Country
- Brazil
- Mexico
- Argentina
- Colombia
- Chile
- Costa Rica
- Puerto Rico
- Rest-of-Latin America
On the basis of country, Brazil segment accounted for the largest share in 2023, holding a 48.35% market share. Mexico is expected to grow at a fastest rate of 10.41% over a forecast period.
Demand - Drivers and Limitations
The following are the demand drivers for Latin America NGS market:
- Rising Demand for NGS Driven by Growing Disease Burden
- Expanding Localized Genomics Infrastructure and Partnerships
The market is expected to face some limitations due to the following challenges:
- Lack of Funding and Reimbursement
- Lack of Education, Awareness, and Specialists
Future Outlook
The Latin America NGS market is poised for significant growth, driven by advancements in sequencing technologies, government investments, and increasing clinical applications. The integration of AI, expansion of population genomics initiatives, and focus on personalized medicine will be pivotal in shaping the market's trajectory. As NGS becomes more accessible, its role in improving healthcare outcomes across the region will continue to expand.
How can this report add value to an organization?
Product/Innovation Strategy: The Latin America NGS market has been extensively segmented on the basis of various categories, such as offering, technology, application, and end-user. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Competitive Strategy: A detailed competitive benchmarking of the players operating in the Latin America NGS market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.
Key Companies Profiled:
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- PacBio
- Agilent Technologies, Inc.
- Oxford Nanopore Technologies plc
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- Revvity, Inc.
- MGI Tech Co., Ltd.
Table of Contents
Executive Summary
Research Methodology
Scope of the Study
1 Market Overview
- 1.1 Product Definition
- 1.2 Inclusion and Exclusion Criteria
- 1.3 Latin America NGS Market Size, $ Million, 2023-2034
- 1.4 Regulatory Landscape for NGS
- 1.4.1 Regulatory Landscape for Latin America
- 1.4.2 Regulatory Landscape for Brazil
- 1.4.3 Regulatory Landscape for Mexico
- 1.4.4 Regulatory Landscape for Colombia
- 1.4.5 Regulatory Landscape for Argentina
- 1.4.6 Regulatory Landscape for Chile
- 1.4.7 Regulatory Landscape for Costa Rica
- 1.4.8 Regulatory Landscape for Puerto Rico
- 1.5 Market Dynamics
- 1.5.1 Market Drivers
- 1.5.1.1 Rising Demand for NGS Driven by Growing Disease Burden
- 1.5.1.2 Expanding Localized Genomics Infrastructure and Partnerships
- 1.5.2 Market Restraints
- 1.5.2.1 Cost Effectiveness
- 1.5.2.2 Lack of Funding and Reimbursement
- 1.5.2.3 Lack of Education, Awareness, and Specialists
- 1.5.3 Market Trends
- 1.5.4 Future Opportunities
- 1.5.4.1 Establishing Diagnostic Centers
- 1.5.4.2 Expanding Genomic Data for Advanced NGS Solutions
- 1.6 NGS-Based Testing Volume Analysis (by Indication), 2023-2033
- 1.6.1 Oncology
- 1.6.2 Rare and Hereditary Diseases
- 1.6.3 Reproductive Health
- 1.6.4 Direct-to-Consumer
- 1.6.5 Infectious Disease Testing
- 1.6.6 Others
- 1.7 NGS-Based Testing Volume Analysis (By Country), 2023-2033
- 1.7.1 Brazil
- 1.7.2 Mexico
- 1.7.3 Argentina
- 1.7.4 Colombia
- 1.7.5 Rest-of-LATAM
- 1.8 LATAM NGS Market Testing Scenario
- 1.8.1 Local (Latin America) Vs Outsourced Testing Scenario
- 1.8.2 NGS-Based Testing Scenario, Outsourced Test Type (by Indication)
- 1.8.3 NGS-Based Testing Scenario, Local Vs Outsourced Test Type (by Country)
- 1.8.3.1 NGS-Based Testing Scenario, Outsourced Test Type, (by Country)
- 1.8.3.2 NGS-Based Testing Scenario, Local Test Type, (by Country)
2 Offering
- 2.1 Growth-Share Matrix
- 2.1.1 Instruments
- 2.1.1.1 Integrated Workflow Instruments
- 2.1.1.2 Sequencing Instruments
- 2.1.1.3 Library Preparation Instruments
- 2.1.2 Kits and Consumables
- 2.1.2.1 Library Preparation Kits
- 2.1.2.2 Target Enrichment Kits
- 2.1.2.3 Sequencing Kits
- 2.1.2.4 Multiuse Kits
- 2.1.3 Software
- 2.1.4 Services
3 Technology
- 3.1 Growth-Share Matrix
- 3.1.1 Ion Torrent Semiconductor Sequencing
- 3.1.2 Reversible Terminator Sequencing
- 3.1.3 Single Molecule Real-Time Sequencing
- 3.1.4 Nanopore Sequencing Technology
- 3.1.5 Other Technology
4 Application
- 4.1 Growth-Share Matrix
- 4.1.1 Clinical
- 4.1.1.1 Oncology
- 4.1.1.1.1 Haematological Malignancy
- 4.1.1.1.2 Solid Tumor
- 4.1.1.2 Neurological Disease Testing
- 4.1.1.3 Reproductive Health Testing
- 4.1.1.4 Rare Disease Diagnostics
- 4.1.1.5 Infectious Disease Testing
- 4.1.1.6 Others
- 4.1.2 Translational Research
5 End-User
- 5.1 Growth-Share Matrix
- 5.1.1 Hospitals and Clinics
- 5.1.2 Academic and Research Institutes
- 5.1.3 Pharmaceutical and Biotechnology Companies
- 5.1.4 Government Laboratories
- 5.1.5 Other End User
6 Country
- 6.1 Overview
- 6.1.1 Brazil
- 6.1.1.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
- 6.1.1.2 Brazil NGS Test Reimbursement Scenario/Insurance Coverage
- 6.1.2 Mexico
- 6.1.2.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
- 6.1.2.2 Mexico NGS Test Reimbursement Scenario/Insurance Coverage
- 6.1.3 Argentina
- 6.1.3.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
- 6.1.3.2 Argentina NGS Test Reimbursement Scenario/Insurance Coverage
- 6.1.4 Colombia
- 6.1.4.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
- 6.1.4.2 Columbia NGS Test Reimbursement Scenario/Insurance Coverage
- 6.1.5 Chile
- 6.1.5.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
- 6.1.5.2 Chile NGS Test Reimbursement Scenario/Insurance Coverage
- 6.1.6 Costa Rica
- 6.1.6.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
- 6.1.6.2 Costa Rica NGS Test Reimbursement Scenario/Insurance Coverage
- 6.1.7 Puerto Rico
- 6.1.7.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
- 6.1.7.2 Puerto Rico NGS Test Reimbursement Scenario/Insurance Coverage
- 6.1.8 Rest-of-Latin America
- 6.1.8.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
- 6.1.8.2 Rest-of-Latin America NGS Test Reimbursement Scenario/Insurance Coverage
7 Competitive Benchmarking and Company Profiles
- 7.1 Latin America NGS Market Share by Company, 2023
- 7.1.1 Company Market Share
- 7.1.2 Key Takeaways
- 7.2 Competitive Benchmarking
- 7.2.1 Key Development Analysis
- 7.2.1.1 Product Launch and Regulatory Approvals
- 7.2.1.2 Merger and Acquisition
- 7.2.1.3 Business Expansion
- 7.2.1.4 Product Upgradation
- 7.2.1.5 Partnership, Collaboration, and Agreement
- 7.3 Installed Base of NGS Instruments by Country, 2023
- 7.4 Company Profiles
- 7.4.1 Illumina Inc.
- 7.4.1.1 Company Overview
- 7.4.1.2 Role of Illumina in the Latin America NGS Market
- 7.4.1.3 Customer Group and Key Competitors
- 7.4.1.4 Analyst Perception
- 7.4.2 Thermo Fisher Scientific Inc.
- 7.4.2.1 Company Overview
- 7.4.2.2 Role of Thermo Fisher Scientific Inc. in the Latin America NGS Market
- 7.4.2.3 Customer Group and Key Competitors
- 7.4.2.4 Analyst Perception
- 7.4.3 QIAGEN N.V.
- 7.4.3.1 Company Overview
- 7.4.3.2 Role of QIAGEN N.V. in the Latin America NGS Market
- 7.4.3.3 Customer Group and Key Competitors
- 7.4.3.4 Analyst Perception
- 7.4.4 PacBio
- 7.4.4.1 Company Overview
- 7.4.4.2 Role of PacBio in the Latin America NGS Market
- 7.4.4.3 Customer Group and Key Competitors
- 7.4.4.4 Analyst Perception
- 7.4.5 Agilent Technologies, Inc.
- 7.4.5.1 Company Overview
- 7.4.5.2 Role of Agilent Technologies Inc. in the Latin America NGS Market
- 7.4.5.3 Customer Group and Key Competitors
- 7.4.5.4 Analyst Perception
- 7.4.6 Oxford Nanopore Technologies plc
- 7.4.6.1 Company Overview
- 7.4.6.2 Role of Oxford Nanopore Technologies plc in the Latin America NGS Market
- 7.4.6.3 Customer Group and Key Competitors
- 7.4.6.4 Analyst Perception
- 7.4.7 Danaher Corporation
- 7.4.7.1 Company Overview
- 7.4.7.2 Role of Danaher Corporation in the Latin America NGS Market
- 7.4.7.3 Customer Group and Key Competitors
- 7.4.7.4 Analyst Perception
- 7.4.8 F. Hoffmann-La Roche Ltd
- 7.4.8.1 Company Overview
- 7.4.8.2 Role of F. Hoffmann-La Roche Ltd. in the Latin America NGS Market
- 7.4.8.3 Customer Group and Key Competitors
- 7.4.8.4 Analyst Perception
- 7.4.9 Revvity, Inc.
- 7.4.9.1 Company Overview
- 7.4.9.2 Role of Revvity, Inc. in the Latin America NGS Market
- 7.4.9.3 Customer Group and Key Competitors
- 7.4.9.4 Analyst Perception
- 7.4.10 MGI Tech Co., Ltd.
- 7.4.10.1 Company Overview
- 7.4.10.2 Role of MGI Tech Co. Ltd in the Latin America NGS Market
- 7.4.10.3 Customer Group and Key Competitors
- 7.4.10.4 Analyst Perception
